{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:33:23Z","timestamp":1791959603831,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T00:00:00Z","timestamp":1502150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Nature Science Foundation of Liaoning Province","award":["2015020411-301"],"award-info":[{"award-number":["2015020411-301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11523-017-0521-6","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T15:40:01Z","timestamp":1502206801000},"page":"827-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase"],"prefix":"10.1007","volume":"12","author":[{"given":"Xiaohui","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,8]]},"reference":[{"key":"521_CR1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining. Nature. 1973;243:290\u20133.","journal-title":"Nature"},{"issue":"6","key":"521_CR2","first-page":"646","volume":"149","author":"S Avil\u00e9sv\u00e1zquez","year":"2013","unstructured":"Avil\u00e9sv\u00e1zquez S, Ch\u00e1vezgonz\u00e1lez A, Mayani H. Tyrosine kinase inhibitors (TKI): a new revolution in the treatment of chronic myeloid leukemia (CML). Gac Med Mex. 2013;149(6):646\u201354.","journal-title":"Gac Med Mex"},{"issue":"5","key":"521_CR3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","volume":"38","author":"M Miura","year":"2015","unstructured":"Miura M. Therapeutic drug monitoring of Imatinib, Nilotinib, and Dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull. 2015;38(5):645\u201354.","journal-title":"Biol Pharm Bull"},{"key":"521_CR4","doi-asserted-by":"crossref","unstructured":"Sacha T. Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis. 2014;6(1):e2014007.","DOI":"10.4084\/mjhid.2014.007"},{"issue":"3","key":"521_CR5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canep.2013.01.002","volume":"37","author":"AM Mendizabal","year":"2013","unstructured":"Mendizabal AM, Garciagonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol. 2013;37(3):247\u201354.","journal-title":"Cancer Epidemiol"},{"issue":"18","key":"521_CR6","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","volume":"125","author":"J Wang","year":"2015","unstructured":"Wang J, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015;125(18):2771\u20138.","journal-title":"Blood"},{"issue":"1","key":"521_CR7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2011.08.003","volume":"79","author":"SC Esteves","year":"2012","unstructured":"Esteves SC, Zini A, Aziz N, et al. Critical appraisal of World Health Organization\u2019s new reference values for human semen characteristics and effect on diagnosis and treatment of subfertile men. Urology. 2012;79(1):16\u201322.","journal-title":"Urology"},{"key":"521_CR8","doi-asserted-by":"crossref","unstructured":"Fava C, Rege-Cambrin G, Saglio G. The choice of first-line chronic myelogenous leukemia treatment. Ann Hematol. 2015;94(2):S123\u201331.","DOI":"10.1007\/s00277-015-2321-3"},{"issue":"12","key":"521_CR9","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1586\/14737140.2013.859074","volume":"13","author":"EJ Jabbour","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013;13(12):1433\u201352.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"521_CR10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.beha.2009.09.008","volume":"22","author":"J Apperley","year":"2009","unstructured":"Apperley J. CML in pregnancy and childhood. Best Pract Res Clin Haematol. 2009;22(3):455\u201374.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"521_CR11","first-page":"477","volume":"22","author":"C XiaoHui","year":"2010","unstructured":"XiaoHui C, Huai G, Yang X. Imatinib effects on fertility and reproductive in patients with chronic myelogenous leukemia (in Chinese, review). Carcinog Teratog Mutagen. 2010;22(6):477\u20139.","journal-title":"Carcinog Teratog Mutagen"},{"issue":"8","key":"521_CR12","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, et al. European leukemia net recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648\u201371.","journal-title":"Leukemia"},{"issue":"4","key":"521_CR13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0253-7613.83107","volume":"43","author":"AM Prasad","year":"2011","unstructured":"Prasad AM, Ramnarayan K, Nalini K, et al. Effect of imatinib on the biochemical parameters of the reproductive function in male Swiss albino mice. Indian J Pharm. 2011;43(4):389\u201392.","journal-title":"Indian J Pharm"},{"key":"521_CR14","doi-asserted-by":"crossref","unstructured":"Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med. 2004;351(20):2134\u20135.","DOI":"10.1056\/NEJM200411113512024"},{"issue":"3","key":"521_CR15","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.fertnstert.2010.08.060","volume":"95","author":"S Mariani","year":"2011","unstructured":"Mariani S, Basciani S, Fabbri A, et al. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril. 2011;95(3):e15\u20137.","journal-title":"Fertil Steril"},{"issue":"4","key":"521_CR16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2605.2007.00755.x","volume":"30","author":"M Nurmio","year":"2007","unstructured":"Nurmio M, Toppari J, Zaman F, et al. Inhibition of tyrosine kinases PDGFR and C-kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl. 2007;30(4):366\u201376.","journal-title":"Int J Androl"},{"issue":"4","key":"521_CR17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.reprotox.2008.03.004","volume":"25","author":"M Nurmio","year":"2008","unstructured":"Nurmio M, Kallio J, Toppari J, et al. Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis. Reprod Toxicol. 2008;25(4):442\u20136.","journal-title":"Reprod Toxicol"},{"issue":"4","key":"521_CR18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.reprotox.2010.12.056","volume":"31","author":"C Heim","year":"2011","unstructured":"Heim C, Minniear K, Dann CT. Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal. Reprod Toxicol. 2011;31(4):454\u201363.","journal-title":"Reprod Toxicol"},{"issue":"8","key":"521_CR19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","volume":"9","author":"E Abruzzese","year":"2016","unstructured":"Abruzzese E, Trawinska MM, De FP, et al. Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol. 2016;9(8):781\u201391.","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"521_CR20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.leukres.2016.07.008","volume":"48","author":"FE Nicolini","year":"2016","unstructured":"Nicolini FE, Alcazer V, Huguet F, et al. CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment. Leuk Res. 2016;48(9):80\u20133.","journal-title":"Leuk Res"},{"key":"521_CR21","doi-asserted-by":"crossref","unstructured":"Jain A, Khadwal A, Prakashet G, al. Cytopathological diagnosis of an unusual cause of malignant Hydrocele. Clin Medicine Insights Pathol. 2016;9(9):29\u201331.","DOI":"10.4137\/CPath.S40517"},{"issue":"3","key":"521_CR22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3346\/jkms.2005.20.3.512","volume":"20","author":"H Kim","year":"2005","unstructured":"Kim H, Chang HM, Ryu MH, et al. Concurrent male Gynecomastia and testicular Hydrocele after Imatinib Mesylate treatment of a gastrointestinal Stromal tumor. J Korean Med Sci. 2005;20(3):512\u20135.","journal-title":"J Korean Med Sci"},{"key":"521_CR23","doi-asserted-by":"crossref","unstructured":"Seymour JF, Grigg A, Reynolds J, et al. Imatinib\u2019s potential effects on fertility, immunity and pulmonary function: a prospective study in patients with previously untreated CML. Blood. 2004;104(11):1020.","DOI":"10.1182\/blood.V104.11.1020.1020"},{"key":"521_CR24","unstructured":"Xiaohui C, Huai G, Yubin C, et al. One case report: a male patient with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies [article in Chinese]. Zhong Guo Yi Yao Dao Bao. 2013;10(1):116\u20137."},{"issue":"1","key":"521_CR25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11845-014-1084-5","volume":"184","author":"A Mukhopadhyay","year":"2015","unstructured":"Mukhopadhyay A, Dasgupta S, Kanti RU, et al. Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy. Ir J Med Sci. 2015;184(1):183\u20138.","journal-title":"Ir J Med Sci"},{"issue":"1","key":"521_CR26","first-page":"6","volume":"33","author":"Q Jiang","year":"2012","unstructured":"Jiang Q, Jiang B, Chen SS, et al. Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors [article in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2012;33(1):6\u20139.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-017-0521-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-017-0521-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-017-0521-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T13:16:00Z","timestamp":1602681360000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-017-0521-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,8]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s11523-017-0521-6","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,8]]}}}